Adipose tissue-derived mesenchymal stem cells' acellular product extracellular vesicles as a potential therapy for Crohn's disease.

Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0050222 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-4652 (Electronic) Linking ISSN: 00219541 NLM ISO Abbreviation: J Cell Physiol Subsets: MEDLINE

Publication: New York, NY : Wiley-Liss
Original Publication: Philadelphia, Wistar Institute of Anatomy and Biology.

Crohn Disease*/metabolism ; Extracellular Vesicles*/metabolism ; Mesenchymal Stem Cells*/metabolism; Adipose Tissue/metabolism ; Humans ; Macrophages/metabolism

The breakdown of gastrointestinal tract immune homeostasis leads to Crohn's disease (CD). Mesenchymal stem cells (MSCs) have demonstrated clinical efficacy in treating CD in clinical trials, but there is little known about the mechanism of healing. Considering the critical roles of macrophage polarization in CD and immunomodulatory properties of MSCs, we sought to decipher the interaction between adipose-derived MSCs and macrophages, including their cytokine production, regulation of differentiation, and pro-/anti-inflammatory function. RNA extraction and next generation sequencing was performed in adipose tissue from healthy control patients' mesentery (n = 3) and CD mesentery (n = 3). Infiltrated macrophage activation in the CD mesentery was tested, MSCs and extracellular vesicles (EVs) were isolated to compare the regulation of macrophage differentiation, cytokines production, and self-renewal capacities in vitro. CD patients' mesentery has increased M1 macrophage polarization and elevated activation. MSCs and their derived EVs, isolated from inflamed Crohn's mesentery, leads to a rapid differentiation of monocytes to a M1-like polarized phenotype. Conversely, MSCs and their derived EVs from healthy, non-Crohn's patients results in monocyte polarization into a M2 phenotype; this is seen regardless of the adipose source of MSCs (subcutaneous fat, omentum, normal mesentery). EVs derived from MSCs have the ability to regulate macrophage differentiation. Healthy MSCs and their associated EVs have the ability to drive monocytes to a M2 subset, effectively reversing an inflammatory phenotype. This mechanism supports why MSCs may be an effective therapeutic in CD and highlights EVs as a novel therapeutic for further exploration.
(© 2022 The Authors. Journal of Cellular Physiology published by Wiley Periodicals LLC.)

FASEB J. 2007 Feb;21(2):325-32. (PMID: 17267386)
Am J Gastroenterol. 2005 May;100(5):1134-42. (PMID: 15842590)
Mediators Inflamm. 2004 Jun;13(3):181-7. (PMID: 15223609)
Int J Mol Sci. 2018 Jun 19;19(6):. (PMID: 29921749)
Bioinformatics. 2011 Nov 1;27(21):2957-63. (PMID: 21903629)
JAKSTAT. 2013 Jul 1;2(3):e24137. (PMID: 24069552)
Lancet. 2016 Sep 24;388(10051):1281-90. (PMID: 27477896)
Hum Gene Ther. 2017 Jul;28(7):534-540. (PMID: 28132518)
Cell. 2020 Oct 29;183(3):666-683.e17. (PMID: 32991841)
Immunity. 2016 Mar 15;44(3):450-462. (PMID: 26982353)
Gut. 2009 Dec;58(12):1629-36. (PMID: 19740775)
Annu Rev Pharmacol Toxicol. 2011;51:267-88. (PMID: 20887196)
Oncotarget. 2017 Dec 14;9(6):7204-7218. (PMID: 29467962)
Cell Death Dis. 2020 Oct 7;11(10):832. (PMID: 33028809)
Nat Biotechnol. 2010 May;28(5):511-5. (PMID: 20436464)
Cancer Lett. 2020 Nov 28;493:120-127. (PMID: 32829006)
Stem Cells. 2017 Apr;35(4):851-858. (PMID: 28294454)
JAKSTAT. 2013 Oct 1;2(4):e27638. (PMID: 24470980)
J Cell Physiol. 2022 Jul;237(7):3001-3011. (PMID: 35522572)
Biomed Res Int. 2016;2016:8634603. (PMID: 27648452)
Oncotarget. 2017 Jun 6;8(23):38008-38021. (PMID: 28402942)
Stem Cells Cloning. 2018 Nov 27;11:95-113. (PMID: 30568468)
Front Pharmacol. 2019 Aug 13;10:891. (PMID: 31456686)
Mol Cells. 2014 Apr;37(4):275-85. (PMID: 24625576)
Blood. 2000 Jan 15;95(2):494-502. (PMID: 10627454)
Front Endocrinol (Lausanne). 2020 Aug 20;11:544. (PMID: 32973677)
Cell. 2018 Oct 4;175(2):372-386.e17. (PMID: 30270042)
J Control Release. 2016 Oct 28;240:349-363. (PMID: 26778695)
J Immunol Res. 2019 Mar 18;2019:1512969. (PMID: 31011585)
Nat Commun. 2018 Aug 15;9(1):3261. (PMID: 30111884)
Cell. 2014 Mar 27;157(1):121-41. (PMID: 24679531)
Intest Res. 2018 Jan;16(1):26-42. (PMID: 29422795)
Eur J Cell Biol. 2020 Aug;99(6):151096. (PMID: 32800275)
Apoptosis. 2020 Oct;25(9-10):632-647. (PMID: 32617785)
Biochem Biophys Res Commun. 2010 May 21;396(1):7-10. (PMID: 20494102)
Stem Cell Res Ther. 2019 Jan 31;10(1):47. (PMID: 30704535)
J Can Assoc Gastroenterol. 2019 Aug;2(3):e1-e34. (PMID: 31294378)
Stem Cell Res Ther. 2016 Aug 31;7(1):125. (PMID: 27581859)
Gut. 2019 Dec;68(Suppl 3):s1-s106. (PMID: 31562236)
Stem Cells Transl Med. 2015 May;4(5):532-7. (PMID: 25829404)
Stem Cells Transl Med. 2018 Jun;7(6):456-467. (PMID: 29635868)
Front Immunol. 2016 Apr 26;7:160. (PMID: 27199985)
Int J Colorectal Dis. 2013 Mar;28(3):313-23. (PMID: 23053677)
Dis Colon Rectum. 2009 Jan;52(1):79-86. (PMID: 19273960)
J Crohns Colitis. 2018 Nov 09;12(10):1139-1150. (PMID: 29309546)
Front Physiol. 2018 Jun 05;9:651. (PMID: 29922170)
Mol Biol Int. 2014;2014:630797. (PMID: 24757565)
J Cell Physiol. 2014 May;229(5):631-9. (PMID: 24311275)
Oncogene. 2013 May 23;32(21):2601-13. (PMID: 22869151)

Kenneth Rainin Foundation

Keywords: Crohn's disease; M1/M2 macrophage polarization; extracellular vesicles; mesenchymal stem cells

Date Created: 20220506 Date Completed: 20220715 Latest Revision: 20221015

20240105

PMC9544647

10.1002/jcp.30756

35522572